[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med; 2003 Jun 12;348(24):2386-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
  • BACKGROUND: Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy.
  • METHODS: From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by local radiotherapy when indicated.
  • The rate of freedom from treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the comparison of the increased-dose BEACOPP group with the COPP-ABVD group and with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88 percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group with the increased-dose BEACOPP group, and P=0.002 for the comparison of the COPP-ABVD group with the increased-dose BEACOPP group).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy
  • [MeSH-minor] Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Leukemia / epidemiology. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Survival Analysis. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Massachusetts Medical Society
  • [CommentIn] N Engl J Med. 2003 Sep 18;349(12):1186-7; author reply 1186-7 [13679536.001]
  • [CommentIn] N Engl J Med. 2003 Jun 12;348(24):2375-6 [12802021.001]
  • [ErratumIn] N Engl J Med. 2005 Aug 18;353(7):744. Dosage error in article text
  • (PMID = 12802024.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; COPP protocol
  •  go-up   go-down


2. van Agthoven M, Sonneveld P, Verdonck LF, Uyl-de Groot CA: Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica; 2005 May;90(5):661-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost determinants in aggressive non-Hodgkin's lymphoma.
  • BACKGROUND AND OBJECTIVES: The 5 factors of the International Prognostic Index (IPI) for aggressive non Hodgkin's lymphoma (NHL) age, disease stage, serum lactate dehydrogenase (LDH), performance status, number of extranodal sites) are validated predictors of a patient's survival.
  • Given the need for economic evaluations, we analyzed whether the IPI and the presence of B-symptoms (night sweats, fever, weight loss) can identify subgroups of patients with favorable or unfavorable cost profiles.
  • DESIGN AND METHODS: Chart data for 374 patients with newly diagnosed stage II-IV aggressive NHL treated between 1993-2001 with CHOP chemotherapy were used.
  • Costs were calculated up to two years from the start of treatment.
  • Regression analyses and non-parametric bootstrap tests were performed to determine the significance of prognostic factors.
  • RESULTS: Mean first-line treatment costs (excluding G-CSF) were pound sterling 10047 (<60 years) and pound sterling 12232 (>60 years).
  • The 5 IPI variables, the 2 IPI risk group variables (resulting from the 5 factors) and B-symptoms all showed significant univariate associations with first-line treatment costs.
  • Lower predictability of total 2-year costs was due to wide variations in second-line treatments.
  • INTERPRETATION AND CONCLUSIONS: The IPI factors and B-symptoms are predictive of treatment costs.
  • The detailed information presented in this paper is of value for those who need to make cost-effectiveness estimations in NHL, which is a relevant topic, given new treatment modalities that are emerging.
  • [MeSH-major] Health Care Costs. Lymphoma, Non-Hodgkin / economics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / economics. Child. Combined Modality Therapy / economics. Cost-Benefit Analysis. Costs and Cost Analysis. Drug Costs. Female. Fever / epidemiology. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / economics. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Neoplasm Proteins / blood. Netherlands / epidemiology. Prognosis. Radiotherapy, Adjuvant / economics. Retrospective Studies. Risk Factors. Severity of Illness Index. Survival Analysis. Sweating. Weight Loss

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921381.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


3. Hines-Thomas MR, Howard SC, Hudson MM, Krasin MJ, Kaste SC, Shulkin BL, Metzger ML: Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica; 2010 Oct;95(10):1691-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma.
  • BACKGROUND: Bone marrow biopsy is considered essential for the staging and risk-adapted treatment of Hodgkin's lymphoma with unfavorable risk features.
  • We reviewed the cases of pediatric Hodgkin's lymphoma in our institution to determine the impact of bone marrow involvement on treatment, relapse, and survival.
  • DESIGN AND METHODS: We reviewed the clinical characteristics and outcome of 383 patients treated for Hodgkin's lymphoma at St. Jude Children's Research Hospital between August 1990 and August 2008.
  • One patient's risk assignment changed from intermediate to unfavorable risk without his chemotherapy being altered.
  • No statistically significant difference was observed between patients with stage IV Hodgkin's lymphoma who did (n=21) and did not (n=61) have bone marrow involvement in 5-year relapse-free survival (89.6± 7% versus 73.9±6.1%; P=0.25) or 5-year overall survival (95.2±8.2% versus 87.3±4.9%; P=0.82).
  • CONCLUSIONS: Although bone marrow involvement changed the stage in 3.1% of pediatric Hodgkin's lymphoma patients, it did not change risk-adapted treatment or prognosis.
  • We conclude that bone marrow biopsy need not be performed at diagnosis in patients who have unfavorable risk features, although this finding should be confirmed by larger prospective studies.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2002 Nov;119(2):408-11 [12406078.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):150-6 [15175959.001]
  • [Cites] N Engl J Med. 1968 May 23;278(21):1179 [5646722.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1733-6 [5121677.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Haematol. 1982 Jul;51(3):345-60 [7104222.001]
  • [Cites] Eur J Haematol. 1987 Jul;39(1):66-70 [3653373.001]
  • [Cites] Eur J Haematol. 1988 Oct;41(4):359-67 [3197822.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1971-80 [1700080.001]
  • [Cites] Chest. 1991 Mar;99(3):784-5 [1995250.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1591-8 [1714950.001]
  • [Cites] Acta Oncol. 1992;31(1):41-2 [1586503.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] Haematologica. 1994 May-Jun;79(3):241-55 [7926973.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):403-9 [7844601.001]
  • [Cites] Leuk Lymphoma. 1997 Jun;26(1-2):171-6 [9250802.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2769-79 [9256118.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):175-7 [9434827.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):603-9 [9469348.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):897-906 [9508171.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1166-78 [10091803.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1875-80 [15536150.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):362-8 [16794504.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):256-64 [17154164.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2008 Mar;52(1):9-16 [18235420.001]
  • [Cites] Neoplasma. 2008;55(2):96-100 [18237246.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):765-8 [17763463.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):820-6 [18422997.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3765-71 [12228196.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1209-18 [11728679.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):441-4 [12406083.001]
  • (PMID = 20494933.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2948094
  •  go-up   go-down


Advertisement
4. Kluin-Nelemans HC: Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma. Croat Med J; 2002 Oct;43(5):561-4
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in treatment of aggressive non-Hodgkin's lymphoma.
  • There is no doubt that autologous stem cell transplantation is useful for patients with relapsed aggressive non-Hodgkin s lymphoma if they are responsive to the chemotherapy given before the transplantation.
  • A small subset of patients with primary refractory disease still profits from this high dose chemotherapy regimen, but only if chemosensitive and if presenting with favorable risk factors at the moment of transplant eligibility.
  • Autologous stem cell transplantation as upfront first line therapy for patients with aggressive non-Hodgkin s lymphoma does not contribute to a better outcome, most certainly not if it concerns patients with a favorable risk profile.
  • There is still some doubt whether there is any place for autologous stem cell transplantation as first line therapy for patients with an unfavorable risk profile.
  • Most randomized studies do not show an advantage, but more data are needed to definitely assess the place for this therapy option.
  • [MeSH-major] Lymphoma, Non-Hodgkin / surgery. Stem Cell Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402396.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Morais A, Barros MH, Hassan R, Morais VL, Muniz MT: Number of involved anatomic areas as a risk predictor in pediatric Hodgkin's lymphoma: a retrospective study. J Pediatr (Rio J); 2009 May-Jun;85(3):236-42
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of involved anatomic areas as a risk predictor in pediatric Hodgkin's lymphoma: a retrospective study.
  • OBJECTIVES: To determine if the number of involved anatomic areas can modify the standard risk groups in pediatric Hodgkin's lymphoma, identifying children who would benefit from a reduction in treatment intensity.
  • METHODS: Retrospective study evaluating age, sex, histology, Ann-Arbor stage, presence of B symptoms, number of involved anatomic areas, risk grouping (favorable vs. unfavorable), and laboratory exams.
  • All patients received doxorubicin-containing chemotherapy.
  • RESULTS: Sixty-nine patients (2-18 years) were included, 68% belonged to the unfavorable risk group.
  • Of the 30 patients with late effects, 21 were in the original unfavorable risk group and 14 (66.6%) could have been reallocated to the favorable risk group based on the number of involved anatomic areas.
  • CONCLUSIONS: If re-stratification had been applied, a considerable number of children would have received less intensive treatment and, consequently, could have had lower chances of late effects.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Endocrine System Diseases / prevention & control. Heart Diseases / prevention & control. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Epidemiologic Methods. Female. Humans. Male. Prognosis. Risk Factors. Sex Factors. Treatment Outcome


6. Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol; 2010 Sep 20;28(27):4199-206
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
  • PURPOSE: Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL).
  • It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied.
  • PATIENTS AND METHODS: Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 × 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT.
  • RESULTS: With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%.
  • BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%).
  • However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%).
  • Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%).
  • Treatment-related toxicity occurred more often in the arms with more intensive therapy.
  • CONCLUSION: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL.
  • Four cycles of ABVD should be followed by 30 Gy of IFRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiation Dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Europe. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20713848.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00264953
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol
  •  go-up   go-down


7. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V, German Hodgkin's Lymphoma Study Group: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol; 2003 Oct 1;21(19):3601-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
  • PURPOSE: To investigate whether radiotherapy can be reduced without loss of efficacy from extended field (EF) to involved field (IF) after four cycles of chemotherapy.
  • PATIENTS AND METHODS: Between 1993 and 1998, patients with newly diagnosed early-stage unfavorable HD were enrolled onto this multicenter study.
  • Patients were randomly assigned to receive cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) + doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for two cycles followed by radiotherapy of 30 Gy EF + 10 Gy to bulky disease (arm A) or 30 Gy IF + 10 Gy to bulky disease (arm B).
  • RESULTS: Of 1,204 patients randomly assigned to treatment, 1,064 patients were informative and eligible for the arm comparison (532 patients in arm A; 532 patients in arm B).
  • The median observation time was 54 months.
  • Five years after random assignment, the overall survival (OSran) for all eligible patients was 91% and freedom from treatment failure (FFTFran) was 83%.
  • CONCLUSION: Radiotherapy volume size reduction from EF to IF after COPP + ABVD chemotherapy for two cycles produces similar results and less toxicity in patients with early-stage unfavorable HD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy / adverse effects. Recurrence. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12913100.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol
  •  go-up   go-down


8. Stanisavljevic NS, Marisavljevic DZ: Weight and body composition changes during R-CHOP chemotherapy in patients with non-Hodgkin's lymphoma and their impact on dose intensity and toxicity. J BUON; 2010 Apr-Jun;15(2):290-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weight and body composition changes during R-CHOP chemotherapy in patients with non-Hodgkin's lymphoma and their impact on dose intensity and toxicity.
  • PURPOSE: To estimate weight and body composition changes during R-CHOP combination therapy in patients with non-Hodgkin's lymphoma (NHL) and their impact on dose intensity (DI) and toxicity.
  • METHODS: We prospectively evaluated body composition in patients with NHL before starting chemotherapy (visit 1), before the 3rd cycle (visit 2) and before the 6th cycle (visit 3).
  • There was no statistically significant change in lean body mass (LBM) during chemotherapy.
  • CONCLUSION: Patients in the study gained weight during chemotherapy with unfavorable changes in body composition.
  • Attempt has been made to identify clinical variables to predict patients at risk for hematologic toxicity, but an approach for individualizing drug dosing should be continued.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Composition. Body Height. Body Weight. Cyclophosphamide. Dose-Response Relationship, Drug. Doxorubicin / analogs & derivatives. Electric Impedance. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone. Retrospective Studies. Vincristine. Weight Gain. Weight Loss. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658724.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


9. Oztürk MA, Barişta I, Altundağ MK, Türker A, Yalçin S, Celik I, Güllü I, Güler N, Ozişik Y, Kars A, Kansu E, Baltali E, Tekuzman G: Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin. Chemotherapy; 2002 Dec;48(5):252-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin.
  • BACKGROUND: We have evaluated the clinical efficacy and toxicity of a modified etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP) chemotherapy regimen that has been used by the Hacettepe University Department of Medical Oncology (Ankara, Turkey) since 1993.
  • METHODS: Thirty-two patients (18 men and 14 women) with refractory or recurrent non-Hodgkin's lymphoma (NHL) were treated with this protocol.
  • Patients were hospitalized during therapy.
  • After two cycles of chemotherapy, clinical efficacy was assessed by clinical examination, chest radiography, ultrasonography and/or computed tomography.
  • The only unfavorable prognostic factor for OS was the presence of bulky disease.
  • Neutropenia developed in 59% of patients, and febrile neutropenia developed in 74% of these patients, requiring hospitalization for an average of 8 days.
  • Three patients died of neutropenia-associated sepsis despite broad-spectrum antibacterial and antifungal treatment.
  • Moreover, significant myelotoxicity was common, and the risk of treatment-related death was 9%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Cytarabine / adverse effects. Cytarabine / therapeutic use. Etoposide / adverse effects. Etoposide / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Methylprednisolone / adverse effects. Methylprednisolone / therapeutic use. Salvage Therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12476042.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


10. Hänel M, Kröger N, Kroschinsky F, Birkmann J, Hänel A, Herbst R, Naumann R, Friedrichsen K, Ehninger G, Zander AR, Fiedler F: Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. J Cancer Res Clin Oncol; 2001;127(6):387-95
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
  • PURPOSE: The aim of the study was to evaluate the feasibility and efficacy of the combination of mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in patients with prognostically unfavorable recurrent and refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
  • METHODS: Forty-six patients (median age 43 years, range 18-63) with relapsed (n = 15) or refractory (n = 31) malignant lymphoma were enrolled (HD, n = 13; low-grade/transformed NHL, n = 4; high-grade NHL, n = 29).
  • A total of 39 patients (85%) showed multiply relapsed diseases with a duration of prior remission of < 12 months (n = 8) or had lymphoma being resistant to prior chemotherapy (n = 31).
  • The MIFAP therapy consisted of fludarabine (15 mg/m2, q. 12 h, day 1-4), cytarabine (50 mg/m2 by continuous infusion (CI) over 22 h, day 1-4), cisplatin (25 or 30 mg/m2 by CI over 24 h, day 1-4), and mitoxantrone (4 mg/m2, day 2-5).
  • Twenty-two patients responding to MIFAP (10 CR, 12 PR) have been consolidated by high-dose therapy (HDT) with hematopoietic stem cell transplantation (SCT).
  • Unfavorable prognostic factors for EFS by univariate analysis were refractory lymphoma and the presence of B-symptoms.
  • Significant prognostic factors for OS were NHL, refractory lymphoma, B-symptoms, and bone marrow involvement.
  • In contrast, non-hematological side effects were moderate, predominantly of WHO grades I and II.
  • Treatment-related mortality with MIFAP was 4% (two patients with septicemia by Aspergillus fumigatus).
  • The observed toxicity seems to be acceptable considering the unfavorable prognosis and intensive pretreatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / administration & dosage. Salvage Therapy. Vidarabine / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Drug Resistance, Neoplasm. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11414199.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; Q20Q21Q62J / Cisplatin; MIFAP regimen
  •  go-up   go-down


11. Klimm B, Eich HT, Haverkamp H, Lohri A, Koch P, Boissevain F, Trenn G, Worst P, Dühmke E, Müller RP, Müller-Hermelink K, Pfistner B, Diehl V, Engert A, German Hodgkin Study Group: Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol; 2007 Feb;18(2):357-63
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
  • BACKGROUND: The optimal treatment of elderly patients with Hodgkin's lymphoma (HL) is still a matter of debate.
  • Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field sizes, that is extended-field (EF) or involved-field (IF) technique when given after four cycles of chemotherapy.
  • PATIENTS AND METHODS: In the multicenter HD8 study of the German Hodgkin Study Group, 1204 patients with early-stage unfavorable HL were randomized to receive four cycles of chemotherapy followed by either radiotherapy (RT) of 30 Gy EF + 10 Gy to bulky disease (arm A) or 30 Gy IF + 10 Gy to bulky disease (arm B).
  • Freedom from treatment failure (FFTF, 64% versus 87%) and overall survival (OS, 70% versus 94%) after 5 years was lower in elderly patients compared with younger patients.
  • CONCLUSION: Elderly patients with early-stage unfavorable HL generally have a poorer risk profile and outcome when compared with younger patients.
  • Treatment with EF-RT instead of IF-RT after chemotherapy has a negative impact on survival of elderly patients and should be avoided.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071932.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


12. Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H: A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol; 2002 Jun;68(6):354-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
  • The purpose of this study was to determine the efficacy of salvage chemotherapy with, P-IMVP-16/CBDCA, consisting of carboplatin (CBDCA), etoposide (VP-16), ifosfamide (IFM), and methotrexate (MTX), for patients with aggressive non-Hodgkin's lymphoma (NHL) who had previously received CHOP [a regimen of cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine), and prednisolone], as first-line chemotherapy.
  • The survival rate for the 25 responders was 48.0% at 1 yr and 24.0% at 2 yr, and the survival rate for the 20 non-responders was 10.0% at 1 yr (P<0.001).
  • Multivariate analysis demonstrated that prior chemotherapy (reduced-dose CHOP for age 70 yr or older) and the number of cases of extranodal involvement (>1) were significant unfavorable factors for overall survival.
  • Non-hematological adverse effects were predominantly mild and tolerable.
  • Unfortunately, the clinical outcome with P-IMVP-16/CBDCA was unfavorable, possibly because the study comprised consecutive patients who had received identified intensive chemotherapy, such as biweekly CHOP.
  • Salvage chemotherapy with P-IMVP-16/CBDCA is not sufficient to cure relapsed or refractory aggressive NHL.
  • Aggressive NHL should be cured by first-line chemotherapy with or without hematopoietic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Methotrexate / administration & dosage. Methylprednisolone / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prospective Studies. Salvage Therapy. Survival Rate. Time Factors. Treatment Failure. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12225393.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; IMVP-16 protocol
  •  go-up   go-down


13. Straus DJ: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma. Recent Results Cancer Res; 2002;159:143-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma.
  • Chemotherapy regimens similar to those used for non-Hodgkin's lymphoma (NHL) not associated with human immunodeficiency virus (HIV) infection have been used for patients with HIV-associated NHL with less success.
  • In a recent trial, patients with intermediate or high-grade NHL were randomized to either low-dose chemotherapy with methotrexate, bleomycin, doxorubicin, vincristine and dexamethasone (m-BACOD) or to standard-dose m-BACOD with sargramostim (granulocyte-macrophage colony-stimulating factor, GM-CSF).
  • Myelosuppression was greater with standard-dose chemotherapy.
  • In univariate and multivariate analyses of 21 pretreatment features of patients in this trial, four factors emerged as adversely prognostic with respect to survival: age >35 years, intravenous drug use, CD4 counts < 100/mm3 and stage III/IV disease.
  • In an analysis using the proportional hazards model, a "favorable" group was defined by patients with 0 or 1 adverse factor (median survival 46 weeks, survival at 144 weeks 29.5%) as compared with an unfavorable group with 3 or 4 adverse factors (median survival 18 weeks, survival at 144 weeks 0).
  • The outcome of these patients may be improving with the use of highly active antiretroviral therapy (HAART), which seems to improve immune function and tolerance of chemotherapy.
  • A recent trial of the AIDS Malignancy Consortium found that low-dose chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone: CHOP) and standard-dose chemotherapy had similar response rates, acceptable toxicity and minimal alterations in cyclophosphamide, doxorubicin and indinavir pharmacokinetics in HIV-associated lymphoma patients also on HAART (stavudine, lamivudine and indinavir).
  • There is a suggestion that Burkitt-type lymphomas may tend to occur in HIV-infected patients with relatively well preserved immune function and CD4 cell counts.
  • Recent results from our institution suggest that similar outcomes are achievable with intensive chemotherapy in patients with Burkitt's lymphomas with or without HIV infection.
  • With improved immune status and improved bone marrow function with the use of HAART, it will probably become more possible to treat many patients with aggressive HIV-associated NHL with more intensive treatment regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, AIDS-Related / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11785838.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] Germany
  • [Number-of-references] 19
  •  go-up   go-down


14. Klimm B, Engert A: Combined modality treatment of Hodgkin's lymphoma. Cancer J; 2009 Mar-Apr;15(2):143-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined modality treatment of Hodgkin's lymphoma.
  • Substantial clinical progress over the last decades has improved the first-line treatment and prognosis of patients with Hodgkin's lymphoma (HL).
  • This success is mainly based on the introduction of combined modality treatment strategies including chemotherapy in all risk groups and important progress in radiation techniques.
  • The knowledge emerging from numerous clinical trials as well as better staging and imaging techniques helped to develop more effective therapies.
  • According to our current knowledge, a stage and risk factor-based allocation into early favorable, early unfavorable, and advanced stages remains a suitable instrument to tailor risk-adapted therapy.
  • In most of the study groups, patients with early stage HL receive 2 to 4 cycles of chemotherapy followed by radiotherapy to the involved field.
  • The treatment for advanced stages usually consists of 6 to 8 cycles, more intensive regimen, and radiotherapy for residual masses.
  • Here, we review results from current clinical trials and discuss new therapeutic approaches in the combined modality treatment of HL.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Combined Modality Therapy. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Humans. Positron-Emission Tomography. Radiotherapy, Adjuvant. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19390310.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  • [Number-of-references] 45
  •  go-up   go-down


15. Centkowski P, Sawczuk-Chabin J, Prochorec M, Warzocha K: Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes. Leuk Lymphoma; 2005 Mar;46(3):471-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma and tuberculosis coexistence in cervical lymph nodes.
  • We describe the case of a 47-year-old man admitted to the Department of Hematology because of fever, enlarged cervical and supraclavicular lymph nodes, hepatosplenomegaly and non-specific lung infiltrations.
  • The histopathological examination of the cervical lymph node revealed Hodgkin's lymphoma (HL) NS type I.
  • Clinical evaluation revealed stage IVB according to Ann Arbor classification and the presence of 5 unfavorable prognostic factors according to the International Prognostic Index.
  • Despite BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), the enlarged lymph nodes, lung infiltrations and fever persisted.
  • The 4 tuberculostatics regimen and ABVD chemotherapy (adriamycin, bleomycin, vincristine, dacarbazine) resulted in a complete clinical response after 3 months of treatment.
  • [MeSH-major] Hodgkin Disease / complications. Lymph Nodes / pathology. Tuberculosis, Lymph Node / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antitubercular Agents / therapeutic use. Humans. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621842.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


16. Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, Carreras E, León A, Arranz R, Fernández de Sevilla A, Zuazu J, García-Laraña J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E: High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol; 2003 Dec;14(12):1768-75
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
  • BACKGROUND: T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin's lymphomas.
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas.
  • However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined.
  • With a median follow-up of 37 months (range 1-133), overall survival (OS), time-to-treatment failure (TTF) and disease-free survival (DFS) at 5 years was 56%, 51% and 60%, respectively; for the 37 patients transplanted in first CR, OS and DFS at 5 years were 80% and 79%, respectively.
  • Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14630683.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine
  •  go-up   go-down


17. Klimm B, Engert A, Diehl V: First-line treatment of Hodgkin's lymphoma. Curr Hematol Malig Rep; 2006 Mar;1(1):51-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment of Hodgkin's lymphoma.
  • Substantial clinical progress over the last decades has made Hodgkin's lymphoma into one of the most curable human cancers in adults.
  • Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related toxicities.
  • Ongoing trials investigate a reduction of chemotherapy doses or cycles and the application of lower radiation doses and smaller radiation field sizes.
  • For patients with a specific high-risk profile, novel approaches with more intense drug combinations are currently being investigated in clinical trials.
  • This review discusses recent approaches to the first-line treatment of early-favorable, early-unfavorable, and advanced-stage Hodgkin's lymphoma.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Alkylating Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infertility, Female / chemically induced. Infertility, Female / prevention & control. Lymphatic Irradiation. Male. Multicenter Studies as Topic. Radiotherapy Dosage. Remission Induction. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002;13 Suppl 1:102-6 [12078888.001]
  • [Cites] Radiother Oncol. 1986 Nov;7(3):215-21 [3544084.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):476-84 [11786577.001]
  • [Cites] J Clin Oncol. 1985 Feb;3(2):207-14 [3838188.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):560-5 [8426624.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] J Clin Oncol. 1986 Sep;4(9):1295-306 [3528400.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):378-82 [1740677.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3601-8 [12913100.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2320-5 [12805333.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3440-6 [12668650.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4238-44 [11709567.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1079-85 [15205202.001]
  • [Cites] N Engl J Med. 2002 May 2;346(18):1417-8 [11986425.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):739-46 [2422994.001]
  • [Cites] JAMA. 1993 Oct 27;270(16):1949-55 [8411552.001]
  • [Cites] Cancer Res. 1966 Jun;26(6):1221-4 [5947345.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):276-82 [14760122.001]
  • [Cites] Cancer. 1975 Jul;36(1):252-9 [54209.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2396-406 [12802025.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:105-10 [1280463.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4285-9 [12586628.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1638-45 [9193364.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2988-94 [12089229.001]
  • [Cites] N Engl J Med. 1991 Aug 29;325(9):599-605 [1861693.001]
  • [Cites] Eur J Cancer. 2002 Mar;38 Suppl 4:S107-13 [11858975.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):971-80 [12837833.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):818-29 [9508162.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1734-9 [12721249.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):27-37 [2433409.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):830-43 [9508163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):487-97 [10653864.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):211-7 [8532908.001]
  • [Cites] Blood. 2003 Jan 15;101(2):420-4 [12509381.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2424-9 [15136597.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):848-53 [9291804.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:138-47 [12078896.001]
  • (PMID = 20425332.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents
  • [Number-of-references] 50
  •  go-up   go-down


18. Klimm B, Engert A, Diehl V: First-line treatment of Hodgkin's lymphoma. Curr Hematol Rep; 2005 Jan;4(1):15-22
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line treatment of Hodgkin's lymphoma.
  • Substantial clinical progress over the last decades has made Hodgkin's lymphoma (HL) into one of the most curable human cancers in adults.
  • Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related toxicities.
  • Ongoing trials investigate a reduction of chemotherapy doses or cycles and the application of lower-radiation doses and smaller radiation field sizes.
  • For patients with a specific high-risk profile, novel approaches with more intense drug combinations are currently being investigated in clinical trials.
  • Here, we review recent approaches in the first-line treatment of early-favorable, early-unfavorable, and advanced-stage HL.
  • [MeSH-major] Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Algorithms. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case Management. Combined Modality Therapy. Female. Humans. Infertility, Female / etiology. Infertility, Female / prevention & control. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Staging. Radiotherapy / methods. Randomized Controlled Trials as Topic. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610655.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


19. Bordonaro R, Petralia G, Restuccia N, Todaro AM, Serraino D, Giuffrida D, Cordio S, Giannitto-Giorgio C, Salice P, Ursino M, Novello G, Marletta F, Manusia M: Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study. Leuk Lymphoma; 2004 Jan;45(1):93-100
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
  • About one-third of the cases of non-Hodgkin's lymphomas occur in patients aged 60 years or more.
  • Nevertheless, there are very few data in the literature regarding the optimal therapeutic approach for both aggressive and indolent histologies.
  • Fludarabine-based combination regimens are an effective choice for younger patients affected by low-grade non-Hodgkin's lymphomas, but there is a lack of information about their tolerability and efficacy in older patients.
  • We performed a phase II study to test the efficacy and safety of the combination of Fludarabine, Mitoxantrone and Dexamethasone (FND) in newly-diagnosed, chemo-naive elderly patients affected by low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors.
  • At a median follow-up of 19 months, the median time for progression-free-survival and the median survival time were not reached yet.
  • When administered as first-line treatment to a population of elderly patients affected by high-risk, low-grade non-Hodgkin's lymphomas, FND showed a high efficacy and a good toxicity profile.
  • Our data compare favorably to those reported for the same schedule administered both as first- or second-line therapy in younger patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dexamethasone / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / drug therapy. Mitoxantrone / therapeutic use. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15061203.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


20. Hartmann P, Rehwald U, Salzberger B, Franzen C, Diehl V: Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection. Expert Rev Anticancer Ther; 2004 Jun;4(3):401-10
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection.
  • Hodgkin's lymphoma is the most common non-AIDS-defining tumor diagnosed in HIV-infected patients.
  • Although the introduction of highly active antiretroviral therapy (HAART) led to a decreased incidence of several malignancies among HIV-infected patients, the incidence of HIV-associated Hodgkin's lymphoma (HIV-HL) has been persistent in recent years.
  • Its unusually aggressive tumor behavior includes a higher frequency of unfavorable histologic subtypes, high stage and extranodal involvement by the time of presentation and poor therapeutic outcome, in comparison with Hodgkin's lymphoma outside the HIV setting.
  • Treatment of HIV-HL is challenging considering the underlying immunodeficiency caused by HIV itself and may increase the risk of opportunistic infections by inducing further immunosuppression.
  • The introduction of HAART has opened a new perspective in the treatment of HIV-associated malignancies.
  • The improved control of HIV infection and the subsequently improved survival rates of HIV-infected patients has changed the goal from tumor control to cure and new treatment approaches with more potent regimens need to be evaluated to improve survival and quality of life in HIV-HL.
  • [MeSH-major] HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Clinical Trials as Topic. Humans

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15161439.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Number-of-references] 91
  •  go-up   go-down


21. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A, Berlin-Frankfurt-Münster group: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol; 2010 Jul 1;28(19):3115-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
  • PURPOSE: The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined.
  • Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1; concomitant therapy consisted of rasburicase, intrathecally (IT) triple drug (methotrexate, cytarabine, and prednisolone) on days 1 and 3 for CNS-positive patients and steroids only for anaphylaxis.
  • Response rate (RR) was set at 45% for unfavorable activity or at 65% for favorable activity.
  • Forty-nine patients were not evaluable for response because of withdrawal from the study (n = 16), IT therapy in CNS-negative patients (n = 8), corticosteroid treatment (n = 3), technical inadequacy of response evaluation (n = 21), or no evaluable lesion (n = 1).
  • Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Fatigue / chemically induced. Female. Fever / chemically induced. Humans. Infant. Infusions, Intravenous. Male. Nausea / chemically induced. Rituximab. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jul 1;28(19):3104-6 [20516430.001]
  • (PMID = 20516455.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


22. Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, Mitsuya H, Kawano F, Masaki Y, Sasaki T, Chou T, Yokozawa T, Tobinai K, Lenograstim/Lymphoma Study Group: A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Jpn J Clin Oncol; 2003 Feb;33(2):78-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
  • BACKGROUND: Peripheral blood stem cell (PBSC) reinfusion has been widely used for hematopoietic reconstitution after high-dose chemotherapy.
  • However, the optimal dose of granulocyte colony-stimulating factor (G-CSF) for PBSC mobilization in combination with chemotherapy for autograft remains unknown.
  • METHODS: To find the optimal dose of glycosylated G-CSF (lenograstim) for PBSC mobilization in combination with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL), we conducted a dose-finding study on 43 newly diagnosed patients who had unfavorable prognostic factors.
  • They received four to six courses of cyclophosphamide, doxorubicin, vincristine and prednisolone combined with lenograstim every 2 weeks (biweekly CHOP therapy).
  • PBSC apheresis was started after the third course of biweekly CHOP therapy.
  • CONCLUSIONS: The present study suggests that the recommended dose of lenograstim for PBSC mobilization with CHOP therapy in untreated NHL is 5 microg/kg.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Lymphoma, Non-Hodgkin / drug therapy. Prednisone / therapeutic use. Recombinant Proteins / administration & dosage. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Antigens, CD34 / blood. Antigens, CD34 / drug effects. Colony-Forming Units Assay. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12629058.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD34; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6WS4C399GB / lenograstim; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


23. Mohammadianpanah M, Ahmadloo N, Mozaffari MA, Mosleh-Shirazi MA, Omidvari S, Mosalaei A: Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience. Ann Hematol; 2009 May;88(5):441-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
  • The aim of this retrospective study was to define the natural history, clinicopathological findings, prognostic factors, and treatment outcome of 43 patients with localized stages I and II primary non-Hodgkin's lymphoma (NHL) of the nasopharynx, followed up in a single institution over a 17-year period.
  • The pathologic reports were classified according to the International Working Formulation (N = 22) or Revised European-American Lymphoma classification (N = 21).
  • The vast majority of patients (88%) were managed with a sequential combination of chemotherapy and radiation therapy.
  • Chemotherapy mainly consisted of 4-8 (median 6) cycles of CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisolone).
  • Involved-field radiation therapy with a median dose of 44 Gy was delivered to the primary site and entire cervical lymph nodes.
  • B-cell types represented 67% of the cases, among which diffuse large B cell was the most common histological subtype.
  • Our limited data suggest that primary nasopharyngeal NHL tends to have aggressive histology and unfavorable clinical course with poor outcome, despite a considerably localized disease at the time of presentation and high frequency of complete initial response rates.
  • Combined modality therapy should be considered for the majority of patients with primary localized nasopharyngeal NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Pharyngeal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nasopharynx. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931844.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, Moretti L, Colombat P, Luminari S, Fabbiano F, Di Renzo N, Goldstone A, Carella AM, EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial: High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol; 2003 Jun 15;21(12):2320-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
  • PURPOSE: To determine whether high-dose therapy (HDT) with autologous stem-cell transplantation (ASCT) should be included in the initial consolidative treatment of patients with advanced, unfavorable Hodgkin's lymphoma (HL).
  • PATIENTS AND METHODS: One hundred sixty-three patients achieving complete remission (CR) or partial remission (PR) with four initial courses of doxorubicin, bleomycin, vinblastine, and dacarbazine, or other doxorubicin-containing regimens, were randomly assigned to receive HDT plus ASCT (83 patients) versus four courses of conventional chemotherapy (80 patients).
  • Unfavorable HL was defined as the presence of at least two of the following poor prognostic factors: high lactate dehydrogenase level, large mediastinal mass (greater than at least 33% of the thoracic diameter), more than one extranodal site, low hematocrit level, and inguinal involvement.
  • RESULTS: At the end of the treatment program, 92% of patients in arm A and 89% in arm B achieved a CR (P =.6).
  • CONCLUSION: Patients with advanced unfavorable HL achieving CR or PR after four courses of doxorubicin-containing regimens have a favorable outcome with conventional chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin. Chi-Square Distribution. Combined Modality Therapy. Dacarbazine. Doxorubicin. Female. Humans. Lomustine. Male. Mechlorethamine. Middle Aged. Prednisone. Procarbazine. Survival Analysis. Transplantation, Autologous. Treatment Outcome. Vinblastine. Vincristine

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Treat Rev. 2003 Dec;29(6):555-9 [14585266.001]
  • (PMID = 12805333.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; CVPP protocol; MOPP protocol
  •  go-up   go-down


25. Miglino M, Santini G, Grasso R, Pietrasanta D, Clavio M, Pierri I, Canepa L, Nati S, Ballerini F, Varaldo R, Palmisano G, Gobbi M: Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation. Haematologica; 2001 Jul;86(7):706-14
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of patients with relapsed or refractory intermediate-high grade non-Hodgkin's lymphoma with bone marrow infiltration undergoing peripheral blood progenitor cell transplantation.
  • We have developed a three-step single strand conformational polymorphism PCR strategy which is able to detect clonal B lymphoid cells at a frequency as low as 1 clonal cell in 10(6) normal cells.
  • DESIGN AND METHODS: Twenty patients with intermediate or high-grade B non-Hodgkin's lymphoma (NHL) were evaluated.
  • Patients were pre-treated with a median of two (range 1-4) conventional chemotherapy lines before high-dose cyclophosphamide (HDCY).
  • Nineteen patients were offered high-dose therapy followed by peripheral blood progenitor cells (PBPC) autografting.
  • RESULTS: MRD analysis was performed for each patient at the end of conventional chemotherapy and every three months after high dose therapy.
  • All these patients achieved complete response (CR) after high dose therapy (HDT).
  • Six patients relapsed after a median time of 24.5 months.
  • INTERPRETATION AND CONCLUSIONS: Whereas the detection of clonal cells in the apheresis samples did not predict an unfavorable outcome, the disappearance of the clonal rearranged band from the BM sample after HDT proved to be a favorable prognostic factor and was associated with long-lasting disease-free status
  • [MeSH-major] Bone Marrow / pathology. Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Adult. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Neoplasm, Residual / pathology. Prognosis. Prospective Studies. Recurrence. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11454525.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


26. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, Nihashi T, Nagai H: Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol; 2009 Apr 10;27(11):1906-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.
  • PURPOSE: To systematically review the prognostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) for interim response assessment of patients with untreated advanced-stage Hodgkin's lymphoma (HL) or diffuse large B-cell lymphoma (DLBCL).
  • Advanced-stage HL studies included few unfavorable-risk patients.
  • CONCLUSION: For low- to intermediate-risk advanced-stage HL, FDG-PET performed after a few cycles of standard chemotherapy seems to be a reliable prognostic test to identify poor responders, warranting prospective studies to assess PET-based treatment strategies.
  • Its use should be reserved for research settings where treatment regimens and imaging conditions are standardized.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography


27. Langouët AM, Brice P, Simon D, Bocaccio C, Munck JN, Fillet G, Peny AM, Salles G, Quesnel B, Lefrere F, Felix R, Gisselbrecht C: Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients. Hematol J; 2001;2(2):81-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patients.
  • PURPOSE: To analyse prognostic factors influencing hematopoietic recovery in patients with aggressive non-Hodgkin's lymphomas prospectively treated with intensive chemotherapy followed by peripheral blood progenitor-cells transplantation.
  • PATIENTS AND METHODS: Untreated patients with at least two unfavorable factors according to the age-adjusted international prognostic index were included in the LNH 93-3 trial.
  • Patients received three cycles of chemotherapy and PBPC were mobilized using filgrastim.
  • In 26 patients for whom administration of G-CSF was randomized, time to neutrophil recovery was significantly shorter for patients treated with G-CSF: 10 vs 13 days (P = 0.0005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11423999.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


28. Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP: Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):860-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
  • PURPOSE: To determine biophysical parameters from the complication probability data during and after radiotherapy of Hodgkin's lymphoma (HL), based on the number of gastrointestinal side effects that were found in the multicenter HD8 trial of the German Hodgkin Lymphoma Study Group.
  • Patients were randomized to receive two cycles of COPP (cyclophosphamide, vincristine, procarbazine, prednisone) alternating with two cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) followed by radiotherapy (RT) of 30 Gy extended field plus 10 Gy to bulky disease (Arm A) or 30 Gy involved field plus 10 Gy to bulky disease (Arm B).
  • From the dose-volume histograms for a "standard patient" (volume intestine 2300 cm3), we determined the normal tissue complication probability (NTCP) (V, D, m, n, TD50), the biophysical parameter TD50, and n (volume dependent) in such a manner that the observed NTCP in Arm A in cases of supradiaphragmatic involvement only and in cases of infradiaphragmatic involvement correlated with the calculated values.
  • The median observation time was 54 months.
  • The overall survival for all eligible patients was 91%, and freedom from treatment failure was 83%.
  • Survival rates at 5 years after start of RT revealed no differences in terms of freedom from treatment failure (85.8% in Arm A, 84.2% in Arm B) and overall survival (90.8% and 92.4%).
  • Concerning gastrointestinal toxicity, the different radiation treatment volumes resulted in different NTCPs.
  • On the basis of these findings, values of n = 0.09 and TD50 = 32 Gy were derived.
  • CONCLUSION: Radiotherapy volume reduction from extended field to involved field after two cycles of COPP/ABVD chemotherapy gives similar results and less toxicity in patients with early-stage, unfavorable HL.
  • [MeSH-major] Gastrointestinal Tract / radiation effects. Hodgkin Disease / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925455.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol
  •  go-up   go-down


29. Tsartsidze E, Betaneli M, Sharikadze N, Shavidze N, Seskuria N: Treatment of aggressive non-Hodgkin's lymphomas. Georgian Med News; 2007 Apr;(145):30-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphomas.
  • The aim of the study was to evaluate overall survival in patients with diagnosis DLBCL, comparing CHOP chemotherapy plus rituximab with CHOP alone, and standard plus intensive regimens (BEAM).
  • 27 patients with diagnosis of diffuse large B-cell lymphomas were under observation.
  • Overall survival therapy was compared in three groups.
  • I- primary refractory patients who undergone chemotherapy with CHOP regimen (9 patents); II - patients refractory to the standard added intensive chemotherapy regimens (BEAM) (10 patients).
  • In summary based on our observations quantity of unfavorable prognostic factors may determine primary refractory patients to standard therapies and first line treatment in CD20 positive cases with CHOP plus Rituximab regimen increased overall survival from 7,4 month to 17 month (p<0,01).
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525494.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


30. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, Guy G, Lapierre F: Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg; 2000 Feb;92(2):261-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracerebral malignant lymphoma: report of 248 cases.
  • OBJECT: The authors present a retrospective analysis of 248 immunocompetent patients with primary intracerebral lymphoma treated at 19 French and Belgian medical centers between January 1980 and December 1995.
  • All tumors available for review were classic diffuse non-Hodgkin's lymphoma, for which the phenotype was determined in 220 patients: 212 (96.4%) were B-cell and eight (3.6%) were T-cell type tumors.
  • A total of 196 tumors were reviewed in 127 patients for whom preoperative computerized tomography and magnetic resonance studies were available.
  • Of the 248 patients studied, 129 (52%) received chemotherapy plus radiation therapy, 60 (24%) received radiation therapy alone, 35 (14%) received chemotherapy alone, and 24 (10%) received no postsurgical treatment.
  • CONCLUSIONS: Using univariate analysis, the authors determined prognostic factors that were significantly associated with a favorable impact on survival including age younger than 60 years, radiation therapy (without evidence of a dose-response relationship), radiation therapy combined with chemotherapy, and chemotherapy consisting of anthracycline.
  • Partial surgical resection was an unfavorable prognostic factor.
  • Multivariate analysis was used to confirm the independent prognostic value of radiation therapy, age, chemotherapy consisting of anthracyclines or methotrexate, and partial surgical resection.
  • This European survey provides a reasonable basis for the treatment of primary intracerebral lymphoma with the following sequence: stereotactic biopsy sampling, chemotherapy with a methotrexate- and anthracycline-based regimen, followed by cranial irradiation.
  • [MeSH-major] Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / pathology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10659013.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


31. Laport GG: Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. Curr Opin Oncol; 2010 Sep;22(5):409-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy.
  • PURPOSE OF REVIEW: The peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin's lymphomas associated with an unfavorable prognosis compared with the B-cell non-Hodgkin's lymphomas.
  • The PTCLs are characterized by high remission rates after frontline therapy, but relapse inevitably occurs.
  • The impact of high-dose chemotherapy with autologous hematopoietic cell transplantation (AHCT) as early consolidation therapy will be the focus of this review.
  • RECENT FINDINGS: In several prospective trials, only PTCL patients with responsive disease after induction chemotherapy proceeded to AHCT.
  • Most of the published trials demonstrated that prognostic models such as the International Prognostic Index and the Prognostic Index for T-cell lymphoma help predict outcome after AHCT.
  • SUMMARY: Current data support the use of AHCT as early consolidation therapy for PTCL patients who are chemosensitive after induction chemotherapy.
  • Additionally, disease relapse remains the leading cause of treatment failure after AHCT, and thus more intensive treatment strategies or better noncross-resistant therapies are greatly needed early in the course of the disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683269.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


32. Jamet B, Saade YA, Torossian F, Bonfils L, Elaerts J: [Cardiac lymphoma disclosed by ischemic accident. A case report]. Ann Cardiol Angeiol (Paris); 2000 Sep;49(6):343-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cardiac lymphoma disclosed by ischemic accident. A case report].
  • [Transliterated title] Lymphome cardiaque révélé par un accident ischémique. A propos d'un cas.
  • We report on the detection of a primitive cardiac lymphoma revealed by a cerebral vascular accident in a context of deterioration of the general state with fever.
  • The echocardiography, in particular the transesophageal ultrasound, suggested the diagnosis of cardiac lymphoma due to the existence of an inhomogeneous multilobar mass invading the right ventricle and largely encompassing the right auricle.
  • The histologic diagnosis of a malignant non-Hodgkin's lymphoma of type B malignancy was confirmed by anatomopathology.
  • The evolution was, unfortunately, rapidly unfavorable, with the patient dying in a state of cerebral suffering despite a combination treatment of chemotherapy and radiotherapy.
  • [MeSH-major] Brain Ischemia / etiology. Heart Neoplasms / complications. Lymphoma, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12555345.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Bogner C, Peschel C, Decker T: Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma; 2006 Feb;47(2):195-205
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
  • Mantle cell lymphoma (MCL) is a distinctive non-Hodgkin's lymphoma sub-type, characterized by over-expression of cyclin D1 as a consequence of chromosomal translocation t(11;14)(q13;q32).
  • MCL remains an incurable disease, combining the unfavorable clinical features of aggressive and indolent lymphomas.
  • The blastic variant of MCL, which is often associated with additional cytogenetic alterations, has an even worse prognosis and new treatment options are clearly needed.
  • Targeting the ubiquitin - proteasome pathway has only recently been identified as a promising new therapeutic option for cancer patients.
  • Interestingly, an increased activity of the proteasome pathway has been described in MCL cells and the inhibition of the proteasome seems to be a promising therapeutic approach for this incurable disease.
  • [MeSH-major] Boronic Acids / therapeutic use. Lymphoma, Mantle-Cell / drug therapy. Protease Inhibitors / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Nov;47(11):2412-3 [17107919.001]
  • (PMID = 16321849.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / Ubiquitin; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 103
  •  go-up   go-down


34. Guidoboni M, Zancai P, Cariati R, Rizzo S, Dal Col J, Pavan A, Gloghini A, Spina M, Cuneo A, Pomponi F, Bononi A, Doglioni C, Maestro R, Carbone A, Boiocchi M, Dolcetti R: Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma. Cancer Res; 2005 Jan 15;65(2):587-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma with poor response to therapy and unfavorable prognosis.
  • [MeSH-major] Antigens, CD40 / pharmacology. Interleukin-4 / pharmacology. Lymphoma, Mantle-Cell / drug therapy. Tretinoin / pharmacology
  • [MeSH-minor] Aged. CD40 Ligand / biosynthesis. Cell Cycle Proteins / metabolism. Cell Proliferation / drug effects. Cell Survival / drug effects. Cyclin D1 / metabolism. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p21. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / metabolism. Female. Humans. Male. Middle Aged. Proteasome Endopeptidase Complex / metabolism. Proteasome Inhibitors. Proto-Oncogene Proteins / metabolism. Receptors, Retinoic Acid / physiology. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695403.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147205-72-9 / CD40 Ligand; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 207137-56-2 / Interleukin-4; 5688UTC01R / Tretinoin; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


35. Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R: Diffuse large B-cell lymphoma: experience from a tertiary care center in North India. Med Oncol; 2010 Jun;27(2):310-8
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma: experience from a tertiary care center in North India.
  • Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL).
  • We undertook a retrospective case record study to determine the clinico-laboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL).
  • Significant differences were observed between favorable (international prognostic index [IPI]-0, 1, and 2) and unfavorable prognosis groups (IPI-3, 4, and 5) with regards to mean hemoglobin levels (P < 0.005), platelet counts (P < 0.05), serum albumin levels (P < 0.05), and erythrocyte sedimentation rates (P < 0.005), thereby suggesting their role as prognostic markers in our population.
  • Among total NHL, the earlier age of onset, male dominant sex ratio, and higher frequency of B symptoms sets apart NHL in Indian population from that in the developed countries.
  • [MeSH-major] Cancer Care Facilities. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Clin Radiol. 2008 Feb;63(2):125-35 [18194687.001]
  • [Cites] J Clin Pathol. 2006 Jan;59(1):48-55 [16394280.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):840-9 [1643616.001]
  • [Cites] Eur J Haematol. 2008 Dec;81(6):448-53 [18691256.001]
  • [Cites] Br J Cancer. 1989 Feb;59(2):276-82 [2930692.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1813-9 [8859197.001]
  • [Cites] J Med Assoc Thai. 1980 Apr;63(4):181-91 [7381353.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):972-7 [4016691.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Oct;5(5):983-1001 [1938764.001]
  • [Cites] Leuk Res. 1985;9(6):799-802 [4010329.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jan;132(1):118-24 [18181663.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1993 Mar;15(2):86-90 [8223131.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Med Oncol. 2000 May;17(2):111-6 [10871816.001]
  • [Cites] Am J Pathol. 1983 Nov;113(2):207-21 [6605690.001]
  • [Cites] IARC Sci Publ. 1997;(143):i-xxxiv, 1-1240 [9505086.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):736-45 [17454632.001]
  • [Cites] Leuk Lymphoma. 2003 Mar;44(3):451-8 [12688314.001]
  • (PMID = 19350421.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Tan WY, Hu DS, Zeng FY, Song QB, Hu S, Wei L, Zhou LQ: [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. Ai Zheng; 2007 Dec;26(12):1360-4
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
  • BACKGROUND & OBJECTIVE: The treatment strategies of Hodgkin's lymphoma (HL) are different according to clinical stage and risk factors, yet the optimal treatment strategy remains unclear.
  • This study was to analyze the treatment results and prognostic factors of stage IA HL.
  • METHODS: According to prognosis, 97 patients with stage IA HL were divided into 3 groups: 7 (7.2%) in very favorable (VF) group, 72 (74.2%) in favorable (F) group, and 18 (18.6%) in unfavorable (UF) group.
  • Short-term treatment outcome and long-term survival were analyzed.
  • RESULTS: Median follow-up time was 65 months.
  • Cox analysis showed that pathologic type (P=0.056) and tumor relapse (P=0.011) influenced OS, and the response to primary treatment (P=0.024) influenced DFS.
  • The occurrence rate of secondary malignancies was 5.2%, including 2 cases of non-Hodgkin's lymphoma.
  • The pathologic type, response to primary treatment and tumor relapse may be independent prognostic factors of stage IA HL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076802.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; MOPP protocol
  •  go-up   go-down


37. Oriuchi N, Higuchi T, Hanaoka H, Iida Y, Endo K: Current status of cancer therapy with radiolabeled monoclonal antibody. Ann Nucl Med; 2005 Jul;19(5):355-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of cancer therapy with radiolabeled monoclonal antibody.
  • Molecular targeting therapy has become a relevant therapeutic strategy for cancer.
  • There are several monoclonal antibodies used for the treatment of malignant tumors.
  • Radioimmunotherapy using 131I- and 90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin's lymphoma (NHL), including patients who are refractory to anti-CD20 monoclonal antibody (rituximab) therapy in the United States.
  • Following the impressive results of therapy using radiolabeled monoclonal antibodies for NHL, radioimmunotherapy for solid tumors has been examined; however, the results were unfavorable and did warrant further clinical trials as a single agent.
  • Future studies on radioimmunotherapy for solid tumors should focus on the new strategies of targeting such as locoregional administration for intraperitoneal dissemination, and combination therapy with chemotherapy or cytostatic therapy.
  • Although radioimmunotherapy for NHL has shown excellent results comparable to aggressive chemotherapy without severe adverse effects, additional clinical trials should be performed to define the proper role of radioimmunoconjugates as a relevant strategy for cure of NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods. Radioimmunotherapy / trends. Radioisotopes / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Humans. Practice Patterns, Physicians'. Radiopharmaceuticals / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164191.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals
  • [Number-of-references] 70
  •  go-up   go-down


38. Zodelava M, Betaneli M, Tsartsidze E, Kharabadze M: Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome. Georgian Med News; 2009 Feb;(167):32-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome.
  • The aim of the study was to determine the prognostic significance of clinical, laboratory and immunological parameters in indolent and aggressive lymphomas, and to evaluate overall survival in different risk category patients.
  • Based on our investigations patients' age, disease stage, number of extra nodal sites involved, patient performance status 2-4 by ECOG, strongly influenced overall survival in the indolent as well as in the aggressive lymphomas.
  • In indolent lymphomas in case of less than three unfavorable prognostic factors patients overall survival was high (41.04 month) in comparison with patients with three or more unfavorable prognostic factors (14.2 month).
  • Efficacy of treatment was studied in indolent lymphomas, which revealed that in case of one or two unfavorable prognostic factors treatment response is high (82-100%), in case of three factors possibility of remission decreases (56%), in regards to four or five unfavorable factors remission rate is the lowest (40%).
  • Patients overall survival rates with diagnosis in aggressive T-cell and B-cell lymphomas were studied.
  • Analysis of results showed that T-cell phenotype strongly influence the survival of patients with diagnosis of aggressive non-Hodgkin's lymphomas, patients' survival is lower in T-cell lymphomas 7.6 month compared with 17.3 month for B-cell lymphomas.
  • In patients with diagnosis of stage III or IV aggressive lymphomas, three or more unfavorable prognostic factors and T-cell phenotype detects patient which are refractory to the standard chemotherapy schedules.
  • In diffuse large B-cell lymphomas according to the CD10 expression (which was used as an unfavorable prognostic factor in high and high intermediate risk groups) and quantity of the unfavorable prognostic factors identified patients which were primary refractory to standard treatment regimens.
  • In addition we could conclude that in indolent and aggressive lymphomas clinical, laboratory and immunological parameters could be used to identify patients which are primary refractory to standard therapies of treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Drug Resistance, Neoplasm. Humans. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276466.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


39. Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hänel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR: ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol; 2000 Jun;79(6):304-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
  • BACKGROUND: This study was performed to examine the efficacy and toxicity of the combination of adriamycin (ADR), methylprednisolone (solumedrol), cytarabine (Ara-C), and cisplatin (CDDP) in patients with recurrent and refractory malignant lymphomas.
  • PATIENTS AND METHODS: Sixty-five patients with Hodgkin's disease (HD) (n=14) or non-Hodgkin's lymphomas (NHL) (n = 51) were enrolled in the study.
  • The ASHAP therapy consisted of ADR (40 mg/m2 by continuous infusion (CI) over 96 h), methylprednisolone (500 mg i.v., days 1-5), Ara-C (2 g/m2 as a 2-h infusion on day 5), and CDDP (100 mg/m2 by CI over 96 h).
  • Thirty-two patients with CR or PR following ASHAP underwent high-dose therapy (HDT) with subsequent hematopoietic stem cell transplantation.
  • Unfavorable prognostic factors for EFS and OS by univariate analysis were an elevated value of the serum lactate dehydrogenase and refractory lymphoma.
  • Non-hematological toxicities such as gastrointestinal side effects, infections, mucositis, renal and neurotoxicity occurred more rarely and reached WHO grades III/IV only occasionally.
  • No treatment-related mortality with ASHAP was observed.
  • CONCLUSIONS: ASHAP is an effective and moderately toxic salvage therapy for patients with recurrent or refractory HD and NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Methylprednisolone Hemisuccinate / administration & dosage. Middle Aged. Recurrence. Salvage Therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10901609.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5GMR90S4KN / Methylprednisolone Hemisuccinate; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; ASHAP protocol
  •  go-up   go-down


40. Müller RP, Eich HT: The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel. Strahlenther Onkol; 2005 Sep;181(9):557-66
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of quality assurance programs for radiotherapy within the German Hodgkin Study Group (GHSG). Introduction, continuing work, and results of the radiotherapy reference panel.
  • BACKGROUND AND PURPOSE: The German Hodgkin Study Group (GHSG), including more than 500 participating centers, established a central radiotherapy (RT) reference center to improve quality of treatment, starting with the first study generation in 1978.
  • More than 11,000 patients with Hodgkin's lymphoma (HL) have been enrolled into these trials.
  • MATERIAL AND METHODS: A panel of expert radiation oncologists (second study generation HD4-6, 1988-1994, and third study generation HD7-9, 1993-1998) retrospectively evaluated the adequacy of treatment fields, applied radiation doses, treatment time, and technical parameters.
  • (1) central prospective radiation oncologic review of cross-sectional imaging (HD10, HD11) to create the individual radiation treatment plan;.
  • RESULTS: A strong achievement of these activities in the era of extended-field RT was to show that major deviations of radiation treatment portals and radiation dose from prospective treatment prescriptions revealed to be unfavorable prognostic factors for patients with early-stage HL (HD4).
  • These procedures had a significant impact on the correctness of stage definition, allocation to treatment groups and on the extension of the IF treatment volume.
  • In the HD12 trial (advanced stages), a multidisciplinary panel of radiation oncologists, radiologists and medical oncologists reviewed all the diagnostic imaging from diagnosis throughout the treatment in comparison to the documentation forms.
  • For patients with poor response to chemotherapy, the panel recommended RT independent of the randomization.
  • This procedure ensured that patients with a poor response to chemotherapy received additional RT.
  • After chemotherapy, 599 patients (56%) showed residual disease (> 1.5 cm), and in 145/1,080 patients (13.5%) the panel recommended additional RT independent of the randomization arm.
  • Rapid online consultation and real-time teleconferences regarding disease involvement, patient management and communication of the RT prescription with connected hospitals proved to be extremely helpful.
  • CONCLUSION: Today, radiation oncologists in the GHSG perform a continuous and efficient QAP to improve treatment quality of study patients.
  • For early favorable and unfavorable HL a central prospective review of all diagnostic imaging is performed by expert radiation oncologists to control the disease extension and to define the IF treatment volume.
  • Participants are trained on the definition of IF-RT by workshops on the occasion of annual GHSG meetings and on the annual meetings of the German Society of Therapeutic Radiation Oncology (DEGRO).
  • For the advanced stages a multidisciplinary panel evaluates the treatment response to chemotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy. Quality Assurance, Health Care. Radiation Oncology / standards. Radiotherapy / standards
  • [MeSH-minor] Disease-Free Survival. Germany. Humans. Multicenter Studies as Topic. Neoplasm Recurrence, Local. Prognosis. Prospective Studies. Radioisotope Teletherapy. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Remote Consultation. Retrospective Studies. Teleradiology. Time Factors

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170482.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement